Anja von Heydebreck

10.8k total citations · 5 hit papers
93 papers, 7.9k citations indexed

About

Anja von Heydebreck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anja von Heydebreck has authored 93 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Anja von Heydebreck's work include Cancer Immunotherapy and Biomarkers (28 papers), Polyomavirus and related diseases (14 papers) and Gastrointestinal Tumor Research and Treatment (14 papers). Anja von Heydebreck is often cited by papers focused on Cancer Immunotherapy and Biomarkers (28 papers), Polyomavirus and related diseases (14 papers) and Gastrointestinal Tumor Research and Treatment (14 papers). Anja von Heydebreck collaborates with scholars based in Germany, United States and France. Anja von Heydebreck's co-authors include Wolfgang Huber, Martin Vingron, Annemarie Poustka, Holger Sültmann, Kevin M. Chin, Bastian Gunawan, James L. Gulley, H. Grote, L. Füzesi and Howard L. Kaufman and has published in prestigious journals such as Circulation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Anja von Heydebreck

93 papers receiving 7.7k citations

Hit Papers

Variance stabilization applied to microarray data calibra... 2002 2026 2010 2018 2002 2016 2017 2011 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Variance stabilization applied to microarray data calibration and to the quantification of differential expression
    2002 1.8k citations Wolfgang Huber, Anja von Heydebreck et al. Bioinformatics profile →
  2. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
    2016 933 citations Howard L. Kaufman, Jeffery S. Russell et al. The Lancet Oncology profile →
  3. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    2017 581 citations Luc Dirix, István Takács et al. Breast Cancer Research and Treatment profile →
  4. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    2011 453 citations Robert Pirker, Jose R. Pereira et al. The Lancet Oncology profile →
  5. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
    2019 319 citations Matthew H. Taylor, Karen Kelly et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anja von Heydebreck Germany 36 4.0k 2.7k 1.9k 1.4k 1.2k 93 7.9k
Selma Ugurel Germany 49 4.9k 1.2× 3.6k 1.3× 843 0.4× 2.5k 1.7× 721 0.6× 236 8.3k
Axel zur Hausen Germany 40 3.5k 0.9× 2.7k 1.0× 676 0.3× 514 0.4× 1.8k 1.5× 140 6.6k
Jane L. Messina United States 53 5.6k 1.4× 2.9k 1.1× 770 0.4× 2.1k 1.4× 667 0.6× 260 9.6k
Karl D. Lewis United States 41 4.9k 1.2× 4.0k 1.5× 813 0.4× 1.5k 1.0× 525 0.4× 177 7.8k
Gerald P. Linette United States 41 5.5k 1.4× 3.6k 1.3× 720 0.4× 3.6k 2.5× 869 0.7× 123 9.2k
Nallasivam Palanisamy United States 50 1.9k 0.5× 5.5k 2.0× 2.1k 1.1× 561 0.4× 3.4k 2.9× 144 9.1k
Alessandro Testori Italy 53 6.0k 1.5× 3.6k 1.3× 893 0.5× 2.6k 1.8× 697 0.6× 213 9.4k
Scott R. Granter United States 47 2.6k 0.6× 4.5k 1.7× 1.3k 0.7× 953 0.7× 1.3k 1.1× 141 9.5k
Xavier Sastre‐Garau France 64 5.4k 1.3× 4.7k 1.7× 3.4k 1.8× 1.4k 1.0× 3.7k 3.1× 219 13.2k
Jaime Rodriguez‐Canales United States 44 2.9k 0.7× 2.7k 1.0× 1.3k 0.6× 1.3k 0.9× 1.7k 1.5× 163 6.8k

Countries citing papers authored by Anja von Heydebreck

Since Specialization
Citations

This map shows the geographic impact of Anja von Heydebreck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja von Heydebreck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja von Heydebreck more than expected).

Fields of papers citing papers by Anja von Heydebreck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja von Heydebreck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja von Heydebreck. The network helps show where Anja von Heydebreck may publish in the future.

Co-authorship network of co-authors of Anja von Heydebreck

This figure shows the co-authorship network connecting the top 25 collaborators of Anja von Heydebreck. A scholar is included among the top collaborators of Anja von Heydebreck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja von Heydebreck. Anja von Heydebreck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Angelo, Sandra P., Célèste Lebbé, Laurent Mortier, et al.. (2024). First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study. ESMO Open. 9(5). 103461–103461. 9 indexed citations
2.
Keilholz, Ulrich, Janice M. Mehnert, Sebastian Bauer, et al.. (2019). Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. 7(1). 12–12. 71 indexed citations
3.
Kaufman, Howard L., Jeffery S. Russell, Omid Hamid, et al.. (2017). Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. Cancer Research. 77(13_Supplement). CT079–CT079. 19 indexed citations
4.
Jérusalem, Guy, Franklin Chen, David R. Spigel, et al.. (2017). OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S252–S252. 19 indexed citations
5.
Dirix, Luc, István Takács, Guy Jérusalem, et al.. (2017). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment. 167(3). 671–686. 581 indexed citations breakdown →
6.
Shapiro, Irina M., H. Grote, Anja von Heydebreck, et al.. (2017). Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.. Journal of Clinical Oncology. 35(15_suppl). 9557–9557. 3 indexed citations
7.
Kelly, Karen, J. R. Infante, Nicholas Iannotti, et al.. (2016). Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial. Open Repository and Bibliography (University of Liège). 1 indexed citations
8.
Apolo, Andrea B., J. R. Infante, Oday Hamid, et al.. (2015). 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial. European Journal of Cancer. 51. S522–S522. 4 indexed citations
9.
Bergmann, Frank, Sebastian Aulmann, Bence Sipos, et al.. (2014). Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 465(6). 661–672. 56 indexed citations
10.
Pujol, Jean-Louis, Robert Pirker, Thomas J. Lynch, et al.. (2013). Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 83(2). 211–218. 4 indexed citations
11.
12.
Pirker, Robert, Jose R. Pereira, Joachim von Pawel, et al.. (2011). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology. 13(1). 33–42. 453 indexed citations breakdown →
13.
Haller, Florian, Abbas Agaimy, Silke Cameron, et al.. (2010). Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. Histopathology. 56(3). 305–318. 17 indexed citations
14.
Friedrich, Katrin, et al.. (2009). Comparative genomic hybridization-based oncogenetic tree model for genetic classification of breast cancer.. PubMed. 31(2). 101–8. 7 indexed citations
15.
Tejpar, Sabine, Marc Peeters, Hans Gelderblom, et al.. (2008). Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study. Annals of Oncology. 19. 125–125. 1 indexed citations
16.
Gunawan, Bastian, Anja von Heydebreck, Bjoern Sander, et al.. (2007). An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. The Journal of Pathology. 211(4). 463–470. 76 indexed citations
17.
Gunawan, Bastian, Anja von Heydebreck, Wolfgang Huber, et al.. (2004). Cytogenetic and morphologic typing of papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Pathology - Research and Practice. 200(4). 303–303. 34 indexed citations
18.
Kaynak, Bogac L., Anja von Heydebreck, Jan Vogel, et al.. (2003). A genome-wide transcriptional fingerprint of normal and malformed human hearts. Max Planck Institute for Plasma Physics. 22 indexed citations
19.
Huber, Wolfgang, Anja von Heydebreck, Holger Sültmann, Annemarie Poustka, & Martin Vingron. (2002). Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 18(suppl_1). S96–S104. 1806 indexed citations breakdown →
20.
Boer, Judith M., Wolfgang Huber, Holger Sültmann, et al.. (2001). Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array. Genome Research. 11(11). 1861–1870. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Selma Ugurel Breakdown of academic impact, for papers by Axel zur Hausen Breakdown of academic impact, for papers by Jane L. Messina Breakdown of academic impact, for papers by Karl D. Lewis Breakdown of academic impact, for papers by Gerald P. Linette Breakdown of academic impact, for papers by Nallasivam Palanisamy Breakdown of academic impact, for papers by Alessandro Testori Breakdown of academic impact, for papers by Scott R. Granter Breakdown of academic impact, for papers by Xavier Sastre‐Garau Breakdown of academic impact, for papers by Jaime Rodriguez‐Canales
Rankless by CCL
2026